Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note ...
Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $5.17
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of ...
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...
Nasdaq4d
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
In the last three months, 11 analysts have published ratings on Sangamo Therapeutics (NASDAQ:SGMO), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...
Thalassemia Market Research by Treatment Type, Type, Distribution Channel, and Region - Global Forecasts 2034-2034
Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...
Truist Financial Keeps Their Buy Rating on Sangamo Biosciences (SGMO)
Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...
Sangamo price target lowered to $5 from $7 at Truist
Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...
Yahoo Finance7d
Sangamo Therapeutics, Inc. (SGMO)
RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...
American Association of Individual Investors1d
Which Is a Better Investment, Biogen Inc. or Natera, Inc. Stock?
Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.